Aktuelle lnformationen zur Urologie

  • K. Dreikorn
Conference paper
Part of the Verhandlungsbericht der Deutschen Gesellschaft für Urologie book series (VBDGUROLOGIE, volume 36)

Zusammenfassung

Von unserem Präsidenten wurde mir die ehrenvolle Aufgabe anvertraut, Ihnen über aktuelle Fragen und Entwicklungen in der Urologie zu berichten. Unter Berücksichtigung des vorgegebenen zeitlichen Rahmens möchte ich im folgenden aus der umfangreichen, seit unserem letzten Kongress verfügbaren Literatur einige mir wichtig erscheinende Themenkreise aufgreifen, kritisch “beleuchten” und “Trends” aufzeigen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Adolphs HD, HP Bastian: Chemoirnmune prophylaxis of superficial bladder tumors: Results after treatment of 130 patients in 4 years. Ural. Res. II: 271–274 (1983)Google Scholar
  2. 2.
    Ahlering TE, G Lieskovsky, DG Skinner: Indications for urethrectomy in men undergoing single stage radical cystectomy for bladder cancer. J. Urol 131: 657–659 (1984)PubMedGoogle Scholar
  3. 3.
    Alken PH, H Riedmüller, R. Hohenfellner: Doppler sonography and B-mode ultrasound scanning in renal stone surgery. Urology 23: 455–460 (1984)PubMedGoogle Scholar
  4. 4.
    Allen JM, JP O’Shea, K Mashiter, G Wiliams, SR Bloom: Advanced carcinoma of the prostate: Treatment with a gonadotropin releasing hormone agonist. Brit. Med. J. 286: 1607–1609 (1983)Google Scholar
  5. 5.
    Allen JM, DJ Kerle, H Ware, A Doble, G Williams, SR Bloom: Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cencer. Brit. Med. J. 287: 1766 (1983)Google Scholar
  6. 6.
    Ayres PH, HM Schol, JL Hudson: A rapid method for preparation of urinary bladder epithelium for flow cytometric analysis. J. Urol. 131: 1202–1205 (1984)PubMedGoogle Scholar
  7. 7.
    Babayan RK, RJ Krane: Carcinoma in situ of the bladder. World J. Urol. I: 70–73 (1983)Google Scholar
  8. 8.
    Banowski LH: Basic microvascular techniques and principles. Urology 23: 495–503 (1984)Google Scholar
  9. 9.
    Bartsch G, G Hohlbrugger, G Mikuz, H Marberger: Transurethral resection in prostatic carcinoma. World J. Urol. I: 36–39 (1983)Google Scholar
  10. 10.
    Beahrs JR, TR Fleming, H Zincke: Risk of local urethral recurrence after radical cystectomy for bladder cancer. J. Urol. 131: 264–266 (1984)PubMedGoogle Scholar
  11. 11.
    Behme-Wechsung D, H Lüchtrath: Morphologische Befunde nach periurethraler Tefloninjektion. Urologe 24: 83–87 (1984)Google Scholar
  12. 12.
    Benson jr. RC, KM Tomera, H Zincke, TR Fleming, DC Utz: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J. Urol. 131: 1103–1106 (1984)PubMedGoogle Scholar
  13. 13.
    Benson RC, JH Kinsey, DA Cortese, GM Farrow, DC Utz: Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy. J. Ural. 130: 1090–1095 (1983)Google Scholar
  14. 14.
    Blinst Italian Cooperative Group: Intravesical doxorubicin for the prophylaxis of superficial bladder tumors. A multicenter study. Cancer 54: 756–761 (1983)Google Scholar
  15. 15.
    Borgmann V, R Nagel, M Schmidt-Gollwitzer, W Hardt: Langzeitsuppression der gonadalen Testosteronproduktion durch den LH-RH-Agonisten (Buserelinacetat; HHoe 766) beim fortgeschrittenen Prostatakarzinom — eine neue Therapieform? Akt. Urol. 13: 200–203 (1982)Google Scholar
  16. 16.
    Borgmann V, R Nagel, H Al-Abadi, M Schmidt-Gollwitzer: Treatment of prostatic cancer with LH-RH analogues. The Prostate 4: 553–568 (1983)PubMedGoogle Scholar
  17. 17.
    Boyd St D, S Raz: Needle bladder neck suspension for female stress incontinence. Urol. Clin. N. Am. II: 357–366 (1984)Google Scholar
  18. 18.
    Bülow H, U Bülow, S Levine, H Wurster, H Frohmüller: Zum gegenwärtigen Stand der transurethralen Laser-Technik in der Behandlung der Harnröhrenstriktur. Urologe A 20: 328–332 (1981)PubMedGoogle Scholar
  19. 19.
    Conolly JG: RE: Immunotherapy of superficial bladder cancer. Letter to the editor. J. Urol. 130: 368–369 (1983)Google Scholar
  20. 20.
    DeKernion JB: Treatment of advanced renal cell carcinoma — Traditional methods and innovative approaches. J. Urol. 130: 2–7 (1983)Google Scholar
  21. 21.
    De Kernion JB, G Sarna, R Figlin, A Lindner, RB Smith: The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol. 130: 1063–1066 (1983)Google Scholar
  22. 22.
    Diamond DA, R Sanders, RD Jeffs: Fetal hydronephrosis: Considerations regarding urological intervention. J. Urol. 131: 1155–1159 (1984)PubMedGoogle Scholar
  23. 23.
    Donohue JP, JM Zachary, BR Maynard: Distribution of nodal metastases in nonseminomatous testis cancer. J. Urol. 128: 315–320 (1982)PubMedGoogle Scholar
  24. 24.
    Droller MJ: Intravesical chemotherapy in the management of carcinoma in situ of the urinary bladder. World J. Urol. I: 103–105 (1983)Google Scholar
  25. 25.
    Droller MJ: The controversial role of radiation therapy as adjunctive treatment of bladder cancer. J. Urol. 129: 897–903 (1983)PubMedGoogle Scholar
  26. 26.
    Droller MJ, JL Hilton: Immunotherapy of metabolic renal cell cancer with poly Ic; LC. Abstrakt Nr. 301. 79. Tagung der American Urological Association New Orleans, 6.–10. Mai 1984Google Scholar
  27. 27.
    Dubin L, RD Amelar: Magnified surgery for epididymovasostomy. Urology 23. 525–528 (1984)PubMedGoogle Scholar
  28. 28.
    Ebner H, R Pust, R Becker, J Kraushaar: Zytologische und impulszytophotometrische Therapiekontrolle und Rezidiverfassung von Blasenkarzinomen unter adjuvanter Chemotherapie. In Huland H, H Klosterhalfen (Herausg.): Therapie und Rezidivprophylaxe oberflächlicher Harnblasenkarzinome 544–55, Thieme Verlag Stuttgart: New York 1984Google Scholar
  29. 29.
    Elder JS, RP Gibbons, RJ Correa jr., GE Brannen: Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. J. Urol. 132: 55–57 (1984)PubMedGoogle Scholar
  30. 30.
    Elder JS, MD Hafermann, RP Gibbons, RG Correa, GE Brannen: Does TUR disseminate prostatic cancer? Abstrakt Nr. 425. 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  31. 31.
    Farsund T, OD Laerum, J Hostmark: Ploidy disturbance of normal-appearing bladder mucosa in patients with urothelial cancer: Relationship to morphology. J. Urol. 130: 1076–1081 (1983)PubMedGoogle Scholar
  32. 32.
    Farsund T, OD Laerum, J Hostmark, G Jordfald: Local chemotherapeutic effects in bladder cancer demonstrated by selective sampling and flow cytometry. J. Urol. 131: 22–32 (1984)PubMedGoogle Scholar
  33. 33.
    Faure N, A Lemay, B Laroche, G Robert, R Flante C Jean, M Thabet, R Roy, ATA Fazekas: Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. The Prostate 4: 604–624 (1983Google Scholar
  34. 34.
    Flanigan RC, CT King, TD Clark, JB Cash, BJ Greenfield, IJ Sniecinski, FJ Primus: Immunohistochemical demonstration of blood group antigens in neoplastic and normal human urothelium: A comparison with standard red cell adherence. J. Urol. 130: 499–503 (1983)PubMedGoogle Scholar
  35. 35.
    Fluchter SH, H Hlobic, R Harzmann, KF Rothe, KH Bichler: Serum- und Gewebe Mitomycin- C Spiegel nach intravesikaler Instillation. Urol. Int. 38: 321–328 (1983)PubMedGoogle Scholar
  36. 36.
    Fossa SD, A Miller, AE Stenwig: Intravesical thiotepa prophylaxis of superficial bladder cancer. Eur. Urol. 9: 207–210 (1983)PubMedGoogle Scholar
  37. 37.
    Fraley EE, PH Lange: Technical nuances of extended retroperitoneal dissection for low-stage non-seminomatous testicular germ-cell cancer. World J. Urol. 2: 43–47 (1984)Google Scholar
  38. 38.
    Frankfurt OS, RP Ruben: Clinical applications of DNA flow cytometry for bladder tumors. Urology 23: 29–34 (1984)PubMedGoogle Scholar
  39. 39.
    Frohmüller H: Radikale Prostatektomie als Behandlungsmethode des lokal begrenzten Prostatakarzinoms. Bericht über das 7. Klinische Wochenende der Urologischen Univ.-Kliniken Mainz, Bern, Berlin-Charlottenburg in Mainz, 1.–3. März 1984. Herausgegeben von R. Hohenfellner und GH Jacobi, Urol. Klinik Mainz.Google Scholar
  40. 40.
    Garibyan H, FWJ Hazebroek, JAR Schulkes, JC Molenaar, NF Dabhoiwala: Microvascular surgical orchidopexy in the treatment of high-lying undescended testes. Brit. J. Urol. 56: 326–329 (1984)PubMedGoogle Scholar
  41. 41.
    Garnick MB, D Schade, M Israel, B Maxwell, JP Richie: Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. J. Urol. 131: 43–46 (1984)PubMedGoogle Scholar
  42. 42.
    Gerber A: The Kock continent ileal reservoir for supravesical urinary diversion. Am. J. Surg. 146: 15–20 (1983)PubMedGoogle Scholar
  43. 43.
    Gerber A, MK Apt, PH Craig: The Kock continent ileostomy. Surg. Gyn. Obstet. 156: 345–350 (1983Google Scholar
  44. 44.
    Gibbons RP, RJ Correa jr., GE Brannen, JT Mason: Total prostatectomy for localized prostatic cancer. J. Urol. 131: 73–76 (1984)PubMedGoogle Scholar
  45. 45.
    Grayhack JT: Prostatic carcinoma: Management. J. Urol. 132: 92 (1984)PubMedGoogle Scholar
  46. 46.
    Green DF, MRG Robinson, R Glashan, D Newling, O Dalesio, PH Smith: Does intravesical chemotherapy prevent invasive bladder cancer? J. Urol. 131: 33–35 (1984)PubMedGoogle Scholar
  47. 47.
    Hanks GE, S Leibel, S Kramer: The dissemination of cancer by transurethral resection of locally advanced prostate cancer. J. Urol. 129: 309–311 (1983)PubMedGoogle Scholar
  48. 48.
    Hansson HA, NG Kock, L Norlén, B Philipson, H Trasti, C Ahrén: Morphological observations in pedicled ileal grafts used for construction of continent reservoirs for urine. Scand. J. Urol. Nephrol. Suppl. 49: 49–61 (1978)Google Scholar
  49. 49.
    Harrison MR, J Anderson, MA Rosen, NA Ross, AG Henrick: Fetal surgery in the primate I. Anesthetic, surgical, and tocolytic management to maximize fetalneonatal survival. J. Ped. Surg. 17: 115–122 (1982)Google Scholar
  50. 50.
    Harrison MR, MS Golbus, RA Filly, PW Callen, M Katz, AA De Lorimier, M Rosen, AR Jonson: Fetal surgery for congenital hydronephrosis. New Engl. J. Med. 306: 591–593 (1982)PubMedGoogle Scholar
  51. 51.
    Harrison MR, MS Golbus, RA Filly, DK Nakayama, PW Callen, AA De Lorimier, H Hricak: Management of the fetus with congenital hydronephrosis. J. Ped. Surg. 17: 728–742 (1982)Google Scholar
  52. 52.
    Harrison MR, RA Filly, MS Globus, RL Berkowitz, PW Callen et al: Fetal treatment 1982. New Engl. J. Med. 307: 1651–1652 (1982)PubMedGoogle Scholar
  53. 53.
    Hartung R, M Meyer-Schwickerath, D Kröpfl: Sonographische Nierensteinlokalisation mit Minischallköpfen. Akt. Urol. 15: 138–142 (1984)Google Scholar
  54. 54.
    Herr WH, CM Pinsky, MR Melamed, WF Whitmore jr.: Long term effect of intravesical BCG on flat carcinoma in situ (CIS) of the bladder. Abstrakt Nr. 144 79. Tagung der American Urological Association. New Orleans 6.–10. Mai 1984Google Scholar
  55. 55.
    Hisazumi H, T Misaki, N Miyoshi: Photoradiation therapy of bladder tumors. J. Urol. 130: 685–687 (1983)PubMedGoogle Scholar
  56. 56.
    Hisazumi H, T Miyoshi, K Naito, T Misaki: Whole bladder wall photoradiation therapy for carcinoma in situ of the bladder: A preliminary report. J. Urol. 131: 884–887 (1984)PubMedGoogle Scholar
  57. 57.
    Hofstaedter F, G Jakse, B Lederer, G Mikuz, R Delgado: Biological behaviour and DNA cytophotometry of urothelial bladder carcinoma. Brit. J. Urol. 56: 289–295 (1984)PubMedGoogle Scholar
  58. 58.
    Hohenfellner R, H Riedmiller: Psoas-Hitch Ureterozystoneostomie S. 257–267 Bericht über das 7. Klinische Wochenende der Urologischen Universätskliniken Mainz, Bern, Berlin-Charlottenburg in Mainz, 1.-3. März 1984. Herausgegeben von R Hohenfellner und J Jacobi.Google Scholar
  59. 59.
    Hofmann W, B Schreiber, ML Mlynek, D Kröpfl, HF Fenkl: Long-term results of prosthetic ureteral replacement in minipigs. Urol. Int. 39: 95–99 (1984)Google Scholar
  60. 60.
    Hofstetter A: Endoskopische Zerstörung von Blasentumoren mit Laser. Urologe A 20: 317–322 (1981)PubMedGoogle Scholar
  61. 61.
    Huben RP: Tumor markers in bladder cancer. Urology 23: 10–14 (1984)PubMedGoogle Scholar
  62. 62.
    Huland H, U Otto: Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Eur. Urol. 9: 84–86 (1983)PubMedGoogle Scholar
  63. 63.
    Huland H, D Gonnersmann, HP Leichtweiss: Die Wirkung von Prostaglandinsynthesehemmern auf den Gefäßspasmus hydronephrotischer Nieren nach kompletter Ureterligatur: Eine physiologische Voraussetzung, die Reversibilität hydronephrotischer Nierenschädigung zu testen. Akt. Urol. 14: 109–114 (1983)Google Scholar
  64. 64.
    Huland H, D Gonnermann, HP Leichtweiss, R. Dietrich-Hennings: Reversibility of preglomerular active vasoconstriction in the first weeks after complete unilateral ureteral obstruction by inhibition of prostaglandin synthesis. J. Urol. 130: 820–824 (1983)PubMedGoogle Scholar
  65. 65.
    Huland H: Technik der endoskopischen Blasenhalssuspension nach Stamey Pereyra. Urologe 24: 90–92 (1984)Google Scholar
  66. 66.
    Huland H, H Bucher: Endoscopic bladder neck suspension (Stamey-Pereyra) in female urinary stress incontinence. Eur. Urol. 10: 238–241 (1984)PubMedGoogle Scholar
  67. 67.
    Huland H, G Klöppel, U Otto, M Droese: The value of histologic grading and staging, random biopsies, tumor and bladder mucosa blood group antigens, in predicting progression of superficial bladder cancer. Eur. Urol. 10: 28–31 (1984)PubMedGoogle Scholar
  68. 68.
    Huland H, U Otto, M Droese, G Klöppel: Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: Influence on recurrence, progression and survival. J. Urol. 132: 27–29 (1984)PubMedGoogle Scholar
  69. 69.
    Jacobi GH, KF Kippel, R Hohenfellner: 15 Jahre Erfahrung mit der radikalen Zystektomie ohne praoperative Radiotherapie beim Harnblasenkarzinom. Akt. Urol 14: 63–69 (1983)Google Scholar
  70. 70.
    Jakse G, F Hofstädter, U Engelmann, GH Jacobi: ABE-antigenicity of transitional cell carcinoma of the urinary bladder in patients subjected to topical chemoprophylaxis. World J. Urol. 1: 82–85 (1983)Google Scholar
  71. 71.
    Jakse G, F Hofstädter, H Marberger: Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: A followup. J. Urol. 131: 41–42 (1984)PubMedGoogle Scholar
  72. 72.
    Jakse G: Therapie des Carcinoma in situ der Harnblase. In: Huland H, H Klosterhalfen (Herausg.): Therapie und Redizivprophylaxe oberflächlicher Harnblasenkarzinome; S. 94–101, Thieme Verlag Stuttgart New York 1984Google Scholar
  73. 73.
    Jauhiainen K, O Alfthan: Die Behandlung von Carcinoma in situ der Harnblase mit Akt. Ural. 15: 129–133 (1984)Google Scholar
  74. 74.
    Jewett MA, JG Herman, JFG Sturgeon, RH Comisarow, RE Alison, MK Gospodarowicz: Expectant therapy for clinical state A nonseminomatous germ-cell testicular cancer? Maybe. World J. Urol. 2: 57–58 (1984)Google Scholar
  75. 75.
    Jocham D, G Staehler, Ch Chaussy, U Löhrs, E Unsöld: Integrale Photoradiotherapie des Blasenkarzinoms nach tumorselektiver Photosensibilisierung mit Hämatoporphyrin-Derivat (HpD). Akt. Urol. 15: 109–115 (1984)Google Scholar
  76. 76.
    Jocham D, G Staehler, Ch Caussy, W Weinsteiner, U Specht, C Hammer, E Unsöld: Pharmakokinetik der photosensibilisierenden Substanz Hämatoporphyrin-Derivat (HpD) im Blasentumorgewebe und normalen Blasengewebe (Ratte). 7. Symposium für exp. Urologie Tübingen, 6.-8. April 1984 Abstract Heft.Google Scholar
  77. 77.
    Johnson DE, RK Lo, AC von Eschenbach, DA Swanson: Surveillance alone for patients with clinical stage I nonseminomatous germ cell tumors of the testis: Reliminary results. J. Urol. 131: 491–493 (1984)PubMedGoogle Scholar
  78. 78.
    Jonas U: A new artificial sphincter for male incontinence. Abstrakt Nr. 356. 79. Tagung der American Urological Association New Orleans, 6.–10. Mai 1984Google Scholar
  79. 79.
    Jonas U: Operative Behandlung der männlichen Sphinkterinsuffizienz: Experimente zur Entwicklung eines neuartigen alloplastischen Sphinkters. S. 355–368 Bericht über das 7. Klinische Wochenende der Urologischen Universitätskliniken Mainz, Bern, Berlin Charlottenburg 1.–3. März 1984. Herausgegeben von R Hohenfellner und J JakobiGoogle Scholar
  80. 80.
    Jonas D, W Weber, H Beckert, B Thoma, B Darn, H Müller, HJ Stutte: Surgery of the primary tumor of metastasizing renal carcinoma. Urol. Int. 39: 110–113 (1984)PubMedGoogle Scholar
  81. 81.
    Kaisary AB, G Williams, PR Riddle: The role of preoperative embolization in renal cell carcinoma. J. Urol. 131: 641–646 (1984)PubMedGoogle Scholar
  82. 82.
    Karlsen S, G Jordfald, H Svaar: A, B and O (H) isoantigens in tumors of the urinary bladder. Urol. Int. 39: 150–153 (1984)PubMedGoogle Scholar
  83. 83.
    Kelly DR, TL Ratliff, A Shapiro, WJ Catalona: Intravesical BCG for superficial bladder cancer. Abstrakt Nr. 539, 79. Tagung der American Urological Association New Orleans, 6.–10. Mai 1984Google Scholar
  84. 84.
    DeKernion JB, M Huang, A Lindner, RB Smith, JJ Kaufman: Management of superficial bladder tumors and urothelial atypia with intravesical bacille Calmette-Guerin. Abstrakt Nr. 142. 79. Tagung der American Urological Association New Orleans, 6.–10. Mai 1984Google Scholar
  85. 85.
    King CT, TD Clark, J Lovett, JB Cash, FJ Primus, JW McRoberts, RC Flanigan: A comparison of clinical course with blood group antigen testing by specific red cell adherence and immunoperaxidase in ureteral and renal pelvic tumors. J. Urol. 130: 871–873 (1983)PubMedGoogle Scholar
  86. 86.
    Klippel KF, CR Alves de Oliveira: Nabelschnurvene als Nierenbecken- und Harnleiterersatz. Akt. Urol. 14: 304–309 (1983)Google Scholar
  87. 87.
    Klug P, R Petschnigg, H Mayer, H Lipsky: Zur Frage der präoperativen Diagnostik der Streßinkontinenz. Urologe 24: 679–72 (1984)Google Scholar
  88. 88.
    Kock NG: Continent ileostomy. Prog. Surg. 12: 180 (1973)PubMedGoogle Scholar
  89. 89.
    Kock NG, AE Nilson, L Norlén, T Sundin, H Trasti: Urinary diversion via a continent ileum reservoir. Scand. J. Urol. Nephrol. 49: 23–31 (1978)Google Scholar
  90. 90.
    Kock NG, AE Nilson, LO Nilsson, LJ Norlén, BM Philipson: Urinary diversion via a continent ileal reservoir: Clinical results in 12 patients. J. Urol. 128: 469–475 (1982)PubMedGoogle Scholar
  91. 91.
    Körner A, P May: Ergebnisse submukoser Tefloninjektion bei weiblicher Harninkontinenz im Vergleich mit anderen Operationsmethoden. Urologe B 24: 77–79 (1984)Google Scholar
  92. 92.
    Konrad G: Die freie Hodentransplantation zwischen eineiigen Zwillingen. S. 305–306. Bericht über das 7. Klinische Wochenende der Urologischen Universitätskliniken Mainz, Bern, Berlin Charlottenburg 1.–3. März 1984Google Scholar
  93. 93.
    Kopper B, G Dhom, G Mast, G Konrad, M Ziegler: Staging des incidental Car-cinema der Prostata durch diagnostische transurethrale Nachresektion. Akt. Ural. 14: 277–280 (1983)Google Scholar
  94. 94.
    Kramer SA: Current status of fetal intervention for congenital hydronephrosis J. Urol. 130: 641–646 (1983)PubMedGoogle Scholar
  95. 95.
    Kurth KH, PA Maksimović, WCJ Hop, FH Schroder, NJ Bakker: Single-dose intravesical epodyl after TUR of TaTCC bladder carcinoma. World J. Urol. 1: 89–83 (1983)Google Scholar
  96. 96.
    Kurth KM, GM Weissglas, JC Romijn, FH Schroder, JW van Dongen: Chemotherapie des Nierenkarzinoms in vitro und in vivo im Modellsystem der nackten Maus. Akt. Urol. 14: 223–229 (1983)Google Scholar
  97. 97.
    Kurth KH, J Clinqualbre, RTD Oliver, CC Schulman: Embolization and subsequent nephrectomy in metastatic renal cell carcinoma. World J. Urol.·2: 122–126 (1984)Google Scholar
  98. 98.
    Kurth KH, L Denis, CC Shulman, R Sylvester, M De Pauw, O Dalesio: Adiuvante Chemotherapie des oberflächlichen Blasenkarzinoms Ta/T 1: Ergebnisse der EORTCStudien. In: Huland H, H Klosterhalfen (Herausg.): Therapie und Rezidivprophylaxe oberflächlicher Harnblasentumoren. S. 56–69, Thieme Verlag Stuttgart-New York 1984Google Scholar
  99. 99.
    Labrie F, A Dupont, A Bleanger: Complete androgen blockage for the treatment of prostate cancer. In: De Vita Jr, VT, S Hellmann, SA Rosenberg: Important advances in oncology. Chapter: Carcinoma of the prostate. JB Lippincott Company, Philadelphia (im Druck)Google Scholar
  100. 100.
    Lamm DL, RM Lucio, DF Reichert, SH Pickett: Oral versus intralesional BCG immunotherapy of murine transitional cell carcinoma. Abstrakt Nr. 37 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  101. 101.
    Lamm DL, VD Stogdill, BJ Stogdill: Complications of BCG immunotherapy in patients with bladder cancer. Abstrakt Nr. 146, 79. Tagung der American Urological Association New Orleans, 6.–10. Mai 1984Google Scholar
  102. 102.
    Lampante L, H Sparwasser, C Charvalakis: Behandlungsergebnisse der Harninkontinenz durch endourethrale submuköse Tefloninjektion. Urologe 24: 80–82 (1984)Google Scholar
  103. 103.
    Lieskovsky G, DG Skinner: Expectant therapy for clinical stage A nonseminomatous germ-cell tumors of the testis? No. World J. Urol. 2: 53–56 (1984)Google Scholar
  104. 104.
    Lundbeck F, P Mogensen, N Jeppesen: Intravesical therapy of noninvasive bladder tumors (Stage TA) with doxorubicin and urokinase. J. Urol. 130: 1087–1089 (1983)PubMedGoogle Scholar
  105. 105.
    Lytton B: Intraoperative ultrasound for nephrolithotomy. J. Urol. 130: 213–217 (1983)PubMedGoogle Scholar
  106. 106.
    Malizia AA, HM Reimann, RP Myers et al: Teflon injected periurethrally: Migration and granulomatous reaction. Abstrakt Nr. 474, 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  107. 107.
    Marras A, G Mereu, C Dessi, A Macciotta: Oligohydramnios and, extrarenal abnormalities in Potter syndrome. J. Ped. 102: 597–598 (1983)Google Scholar
  108. 108.
    Marshall FF: The in situ surgical management of renal cell carcinoma and transitional cell carcinoma of the kidney. World J. Ural. 2: 130–135 (1984)Google Scholar
  109. 109.
    Marshall FF, PC Walsh: In situ management of renal tumors: Renal cell carcinoma and transitional cell carcinoma. J. Ural. 131: 1045–1049 (1984)Google Scholar
  110. 110.
    Martinez-Pineiro JA: BCG vaccine in superficial bladder tumors: Eight years later. Eur. Urol. 10: 93–100 (1984)PubMedGoogle Scholar
  111. 111.
    Mebust WK, JW Weigel, KR Lee, GG Cox, WR Jewell, EC Krishan: Renal cell carcinoma- Angioninfarction. J. Urol. 131: 231–235 (1984)PubMedGoogle Scholar
  112. 112.
    Mishina T, H Watomabe, T Fujiwara, T Kobayaski, M Maegawa, M Nakow, S Nakayawa: Prophylactic use of mitomycin C bladder instillation for preventing the recurrence of bladder tumors. Abstracts 19. Intern. Cong. Soc. Int. Ural. San Francisco, 5.–10. Sept. 87: 269 (1982)Google Scholar
  113. 113.
    Montie JE, RA Straffon, BH Stewart: Radical cystectomy without radiation therapy for carcinoma of the bladder. J. Urol. 131: 477–482 (1984)PubMedGoogle Scholar
  114. 114.
    Morales A: A controlled trial of surgery versus surgery plus immunotherapy in localized renal cancer. Abstract Nr. 296. 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  115. 115.
    Nagel R, W Leistenschneider, A Knipper: Derzeitiger Stand der Therapie des Prostatakarzinoms. Helv. chir. Acta 50: 321–335 (1983)PubMedGoogle Scholar
  116. 116.
    Nakano E, T Sonoda, H Jujjoka, A Okuyama, M Matsuda, M Osafune: Spontaneous regression of pulmonary metastases after nephrectomy for renal cell carcinoma. Eur. Urol. 10: 212–213 (1984)PubMedGoogle Scholar
  117. 117.
    Nakatsu H, I Kobayashi, Y Onishi, M Igawa, H Ito, E Tahara, H Nihira: ABO (H) blood group antigens and carcinoembryonic antigens as indicators of malignant potential in patients with transitional cell carcinoma of the bladder. J. Urol. 131: 252–257 (1984)PubMedGoogle Scholar
  118. 118.
    Novick AC, BH Stewart, RA Straffon, LH Banowski: Partial nephrectomy in the treatment of renal adenocarcinoma. J. Urol. 118: 932–936 (1977)PubMedGoogle Scholar
  119. 119.
    Otto U, H Huland, H Baisch, G Klöppel: Transplantation of human renal cell carcinoma into NMRI NU/NU mice. II. Evaluation of response to vinblastine sulfate monotherapy. J. Urol. 131: 134–138 (1984)PubMedGoogle Scholar
  120. 120.
    Otto U: Rezidivprophylaxe oberflächlicher Blasenkarzinome — Literaturübersicht. In: Huland H Und H Klosterhalfen (Herausg.) Therapie und Rezidivprophylaxe oberflächlicher Blasentumoren. S. 1–8, Georg Thieme Verlag Stuttgart-New York 1984Google Scholar
  121. 121.
    Pain JA, DGSTJ Collier: Factors influencing recurrence of urethral strictures after endoscopic urethrotomy: the role of infection and perioperative antibiotics. Brit. J. Urol. 56: 217–219 (1984)PubMedGoogle Scholar
  122. 122.
    Paulson DF and the Uro-Oncology research group: Radical surgery for the management of prostatic carcinoma. World J. Urol. 1: 29–35 (1983)Google Scholar
  123. 123.
    Paulson DF, GH Lin, W Hinshaw, S Stephani and the Uro-Oncology Research group: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J. Urol. 128: 502–504 (1982)PubMedGoogle Scholar
  124. 124.
    Pearson JF: Fetal surgery. Arch. Dis. Child 58: 324–325 (1983)PubMedGoogle Scholar
  125. 125.
    Peckham MJ, A Barrett, TJ McElwain, WF Hendry, D Raghavan: Non-seminoma germ cell tumors (malignant teratoma) of the testis. Brit. J. Urol. 53: 162–172 (1981)PubMedGoogle Scholar
  126. 126.
    Peckham MJ, JE Husband, A Barrett, WF Hendrys: Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumors. Lancet II: 672–680 (1982)Google Scholar
  127. 127.
    Pont A, PL Williams, S Azhar, RE Reitz: Ketoconazole blocks testosterone synthesis. Arch. Intern. Med. 142: 2137–2140 (1982)PubMedGoogle Scholar
  128. 128.
    Pont A, PL Williams, DS Loose, D Feldman, RE Reitz, Ch Bochra, DA Stevens: Ketoconazole blocks adrenal steroid synthesis. Ann. Int. Med. 97: 370–372 (1982)PubMedGoogle Scholar
  129. 129.
    Prout jr. GR, WW Koontz jr., LJ Coombs, IR Hawkins, GH Friedell: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J. Urol. 130: 677–680 (1983)PubMedGoogle Scholar
  130. 130.
    Raghavan D: Expectant therapy for clinical stage a nonseminomatous germ-cell cancers of the testis? A qualified “yes”. World J. Urol. 2: 59–63 (1984)Google Scholar
  131. 131.
    Rassweiler J, GW Kauffmann, R Jäger, R Rohrbach: Die kapilläre Embolisation mit ethibloc bei renaler Hypertonie — eine Alternative zur Nephrektomie? Akt. Urol. 15: 1–8 (1984)Google Scholar
  132. 132.
    Richie JP, MB Garnick: Changing concepts in the treatment of nonseminomatous germ cell tumors of the testis. J. Urol. 131: 1089–1092 (1984)PubMedGoogle Scholar
  133. 133.
    Riedmiller H, E Becht, L Hertle, G Jacobi, R Hohenfellner: Psoas-hitch ureteroneocystostomy: experience with 181 cases. Eur. Urol. 10: 145–150 (1984)PubMedGoogle Scholar
  134. 134.
    Rosenthal CL, R Kraft, EJ Zingg: Organ-preserving surgery in renal cell carcinoma: Tumor enucleation versus partial kidney resection. Eur. Urol. 10: 222–228 (1984)PubMedGoogle Scholar
  135. 135.
    Rothauge CF: Urethroscopic recanalisation of urethral stenosis using argon laser. Urology 16: 158 (1980)PubMedGoogle Scholar
  136. 136.
    Rothauge CF, HD Nöske, J Kraushaar: Erfahrungen mit der Argon-Laserapplikation bei urologischen Erkrankungen. Urologe A 20: 333–339 (1981)PubMedGoogle Scholar
  137. 137.
    Rübben H: Experimentelle und klinische Ergebnisse der endovesikalen Chemo Rezidivprophylaxe mit adriamycin. In: Huland H, H Klosterhalfen (Herausg.): Therapie und Rezidivprophylaxe oberflächlicher Harnblasenkarzinome. S. 70–83 Thieme Verlag Stuttgart-New York 1984Google Scholar
  138. 138.
    Rübben H, R Hautmann, HH Dahm: Bladder tumor induction by cytotoxic agents. World. J. Urol. 1: 94–99 (1983)Google Scholar
  139. 139.
    Schacher A, MF El Etreby, F Neumann: Einfluß von Cyproteronacetat, Flutamid und Spironolacton auf die Achse Hypothalamus — Hypophyse-Hoden bei Ratten. Akt. Urol. 15: 218–225 (1984)Google Scholar
  140. 140.
    Schaeffer AJ, TA Stamey: Endoscopic suspension of vesical neck for urinary incontinence. Urology 23: 484–494 (1984)PubMedGoogle Scholar
  141. 141.
    Schellhammer PF, SS Warden, LE Ladaga: Bacillus Calmette-Guerin (BCG) in the treatment of transitional cell carcinoma of the bladder. Abstract Nr. 143. 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  142. 142.
    Schmidbauer CP, P Porpaczy, A Georgopoulus, H Rameis: Absorption of doxorubicin- hydrochloride and mitomycin-C. afrer insrillation into noninfected and infected bladder of dogs. J. Urol. 131: 818–821 (1984)PubMedGoogle Scholar
  143. 143.
    Schneider HJ, EW Rugendorff: Die Behandlung der Harninkontinenz durch endourethrale submuköse Tefloninjektion. Urologe 24: 73–76 (1984)Google Scholar
  144. 144.
    Schreiter F: Meshgraft — Urethroplastik: persönliche Erfahrungen mit 64 Patienten. s. 371–383, Bericht über das 7. Klinische Wochenende der Urologischen Universitätskliniken Mainz, Bern, Berlin Charlottenburq 1.–3. März 1984, Herausgegeben von R Hohenfellner und J Jakobi.Google Scholar
  145. 145.
    Schroeder FH, JHM Blom, WCJ Hop, FK Mostofi: Ircidental carcinoma of tPe prostate treated by total prostatectomy. World J. Urol. 1: 15–23 (1983)Google Scholar
  146. 146.
    Schulman CC, LJ Denis, W Oosterlinck, W De Sy, M Chantrie, C Bouffioux, PJ van Cangh, P van Erps: Early adjuvant adriamycin in superficial bladder carcinoma. World J. Urol. 1: 86–88 (1983)Google Scholar
  147. 147.
    Schulman CC, J Simon, EWF Germeau: Endoscopic injection of teflon for female urinary incontinence. Eur. Urol. 9: 246–247 (1983)PubMedGoogle Scholar
  148. 148.
    Schülke J: Komplikationen bei der transurethralen Tefloninjektion zur Behandlung der Harninkontinenz. Urologe 24: 88–89 (1984)Google Scholar
  149. 149.
    Silber SJ: Microsurgery for vasectomy reversal and vasoepididymostomy. Urology 23: 505–524 (1984)PubMedGoogle Scholar
  150. 150.
    Sidi AA, RK Chiou, PH Lange: Recent reflections on tumor markers. World J. Urol. 2: 18–25 (1984)Google Scholar
  151. 151.
    Skinner DG, SD Boyd, G Lieskovsky: Creation of a continent (KOCK) ileal reservoir for cutaneous urinary diversion. Abstract Nr. 44, 79. Meeting der American Urological Association New Orleans, 6.–10. Mai 1984Google Scholar
  152. 152.
    Snyder H, Mc C, JW Duckett: Orchidopexy with division of spermatic vessels: Review of 10 years experience. Abstrakt Nr. 89. 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  153. 153.
    Smith jr. JA: Androgen suppresion by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J. Urol. 131: 1110–1112 (1984)PubMedGoogle Scholar
  154. 154.
    Smith jr. JA, JA Dixon: Argon laser phototherapy of superficial transitional cell carcinoma of the bladder. J. Urol. 131: 655–656 (1984)PubMedGoogle Scholar
  155. 155.
    Smith jr. JA, JA Dixon: Laser photoradiation in urologic surgery. J. Urol. 131: 631–635 (1984)PubMedGoogle Scholar
  156. 156.
    Smith jr. JA, JA Dixon: Neodym-Yag laser treatment of benign urethral strictures. J. Urol. 131: 1080–1081 (1984)PubMedGoogle Scholar
  157. 157.
    Soloway MS: Superficial bladder cancer: Comments on evaluation and management. J. Urol. 132: 91 (1984)PubMedGoogle Scholar
  158. 158.
    Soloway MS, AF Blatnik, WM Murphy: Comparison of intravesical BCG with intravesical chemotherapy in murine bladder cancer. Abstrakt Nr. 654, 79. Tagung der American Urological Association, New Orleans, 6.–10. Mai 1984Google Scholar
  159. 159.
    Srinivas V, HG Kiruluta: ABO (H)Isoantigens in bladder tumors: A new technique of quantitative analysis. J. Urol. 131: 245–248 (1984)PubMedGoogle Scholar
  160. 160.
    Staebler G, A Hofstetter, E Schmiedt, E Rother, W Gorisch, W Weinberg: Endoblase. Urol. Int. 39: 143–146 (1984)Google Scholar
  161. 161.
    Staehler G, A Hofstetter, E Schmiedt, E Rother, W Gorisch, W Weinberg: Endoskopische Laser-Bestrahlung von Blasentumoren des Menschen. Fortschr. Med. 95: 3 (1977)PubMedGoogle Scholar
  162. 162.
    Stein BS, AR Kendall: Lasers in urology. I. Laser physics and safety. Urology 23: 405–410 (1984)PubMedGoogle Scholar
  163. 163.
    Stein BS, AR Kendall: Lasers in urology. II. Laser therapy. Urology 23: 411–416 (1984)PubMedGoogle Scholar
  164. 164.
    Stevens DA, PL Williams, AM Sugar, A Pont: Ketoconazole effects. Ann. Int. Med. 97: 284–285 (1982)PubMedGoogle Scholar
  165. 165.
    Studer UE, E Ruchti, RM Greiner, EJ Zingg: Faktoren, welche die Überlebensrate nach totaler Zystektomie wegen Harnblasenkarzinom beeinflussen. Akt. Urol. 14: 70–77 (1983)Google Scholar
  166. 166.
    Sturgeon JFG, JG Herman, MAS Jewett et al: A policy of surveillance alone after orchidectomy for clinical stage A, non seminomatous testis tumors. (Abstract C–558) Proc. Am. Soc. Clin. Oncol. 2: 142 (1983)Google Scholar
  167. 167.
    Swanson DA, DE Johnson, AC von Eschenbach, VP Chuang, S Wallace: Angioinfarction plus nephrectomy for metastatic renal cell carcinoma-an update. J. Urol. 130: 449–452 (1983)PubMedGoogle Scholar
  168. 168.
    Topley M, AC Novick, JE Montie: Long-term results following partial nephrectomy for localized renal adenocarcinoma. J. Urol. 131: 1050–1052 (1984)PubMedGoogle Scholar
  169. 169.
    Trachtenberg J, N Halpern, A Pont: Ketoconazole: A novel and rapid treatment for advanced prostatic cancer. J. Urol. 130: 152–153 (1983)PubMedGoogle Scholar
  170. 170.
    Trachtenberg J: Ketoconazole therapy in advanced prostatic cancer. J. Urol. 132: 61–63 (1984)PubMedGoogle Scholar
  171. 171.
    Trachtenberg J: Ketoconazole is effective in the treatment of advanced human prostatic cancer. Abstrakt Nr. 415. 79. Tagung der American Urological Association. New Orleans, 6.–10. Mai 1984Google Scholar
  172. 172.
    Tsuchiya A, N Obara, M Miwa, T Ohi, H Kate, Y Hayata: Hematoporphyrin derivative and laser photoradiation in the diagnosis and treatment of bladder cancer. J. Urol. 130: 79–82 (1983)PubMedGoogle Scholar
  173. 173.
    Vafier Lt J, N Javadpour, CGF Worsham, KJO-Connell: Double blind comparison of T-antigen and ABO (H) cell surface antigens in bladder cancer. Urology 23: 348–351 (1984)PubMedGoogle Scholar
  174. 174.
    Vallancien G, PH Rouger, JP LeClerc, R Kuss: Immunofluorescence study of the distribution of A, Band H cell surface antigens in bladder tumors. J. Urol. 130: 67–70 (1983)PubMedGoogle Scholar
  175. 175.
    Majsman Z, RA Dhafir, M Pfeffer, S MacDonald, A Block, N Dragone, JE Pontes: Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors. J. Urol. 132: 30–33 (1984)Google Scholar
  176. 176.
    Walker KJ, RI Nicholson, AO Turkes, A Turkes, K Griffiths, M Robinson, S Dris, Z Crispin: Therapeutic potential of the LHRH agonist, ICI 118630, in the. treatment of advanced prostatic carcinoma. Lancet 2: 413–415 (1983)PubMedGoogle Scholar
  177. 177.
    De Wall JG, KH Kurth, AT van Ooserom, R De Laat, EAJM De Jong: Plasma levels of mitomycin-C during it’s intravesical instillation.Google Scholar
  178. 178.
    Walsh PC, PG Denker: Impotence following radical prostatectomy: Insight into etiology and prevention. J. Urol. 128: 492–497 (1982)PubMedGoogle Scholar
  179. 179.
    Walsh PC, H Leper, JC Eggleston: Radical prostatectomy with preservation of sexual function. Anatomical and pathological considerations. The Prostate 4: 473–485 (1983)PubMedGoogle Scholar
  180. 180.
    Walzer Y, RB Matheny, AF Blatnik, MMS Soloway: Urothelial trauma — a mechanism of tumor promotion? World J. Urol. 1: 100–102 (1983)Google Scholar
  181. 181.
    Weinstein RS, AW Miller III , BU Pauli: Carcinoma in situ: Comments on the pathobiology of a paradox. Urol. Clin. North Am. 7: 523–531 (1980)PubMedGoogle Scholar
  182. 182.
    Weissbach L, EA Boedefeld, W Oberdörster, W Vahlensieck: Therapy in stage I non-seminomatous testicular tumor. Eur. Urol. 10: 1–9 (1984)PubMedGoogle Scholar
  183. 183.
    Weldon TE, MS Soloway: Susceptibility of urothelium on neoplastic cellular implantation. Urology 5: 824–827 (1975)PubMedGoogle Scholar
  184. 184.
    Wenderoth UK, J Happ, U Krause, H Adenauer, GH Jacobi: Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients. Eur. Urol. 8: 343–347 (1982)PubMedGoogle Scholar
  185. 185.
    Wenderoth UK, GH Jacobi: Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. A new approach to the classical concept. World J. Urol. 1: 40–48 (1983)Google Scholar
  186. 186.
    Weyrauch HM, JH Crossfield: Dissemination of bladder neoplasms by endoscopic electroresection. J. Urol. 87: 391 (1962)PubMedGoogle Scholar
  187. 187.
    Whitaker RH, MS Buxton-Thomas: Comparison of pressure flow studies and renography in equivocal upper urinary tract obstruction. J. Urol. 131: 446–449 (1984)PubMedGoogle Scholar
  188. 188.
    Williams G, JM Allen, D Kerle, H Ware, SR Bloom: Testicular and adrenal testosterone ablation using combined LHRH analogue and ketokonazole for advanced progressive carcinoma of the prostate. Abstrakt Nr. 423. 79. Tagung der American Urological Association, New Orleans, 6.–10. Mai 1984Google Scholar
  189. 189.
    Wolk FN, MC Bishop: The specific red cell adherence test in transitional cell carcinoma of the bladder before and after radiotherapy in patients with blood group A. J. Urol. 130: 71–73 (1983)PubMedGoogle Scholar
  190. 190.
    Zincke H, SK Swanson: Bilateral renal cell carcinoma: Influence of synchronous and asynchronous occurrence on patient survival. J. Urol. 128: 913–915 (1982)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • K. Dreikorn
    • 1
  1. 1.Urologische Abteilung des Chirurgischen ZentrumsUniversität HeidelbergHeidelbergDeutschland

Personalised recommendations